Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks
John M.L. Ebos and Roberto Pili
See article p. 3961

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Cure Models as a Useful Statistical Tool for Analyzing Survival
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi and Pasi A. Jänne

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paola Dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman
3803 Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Luigi Scotto, Marianna Kruthof-de Julio, Luca Paoluzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O’Connor

3812 Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O’Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler

3822 Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O’Sullivan, Daniel B. Longley, and David J.J. Waugh

3834 Development of an Fc-Enhanced Anti–B-7-H3 Monoclonal Antibody with Potent Antitumor Activity

3846 Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
Harvey Wong, Edna F. Choo, Bruno Aliche, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould

3856 Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson

3868 Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spilia, Jhessica Alessandroni, Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong Yok Tsang, Jeffrey Schlom, and Claudia Palena

3880 Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann

3889 Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Abbes Belkhiri, Shoumin Zhu, Zheng Chen, Mohammed Soutto, and Wael El-Rifai

3901 GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath

3912 AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

3924 Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata
Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma
Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nennati, Didier Decaudin, François-Clement Biedard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival
Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier

Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis
Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang

Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients
Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maozheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dullois, Ernest T. Hawk, and Xifeng Wu

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
Yu-Yun Shao, Chien-Chung Huang, Shihou-Der Lin, Chih-Hung Hsu, and Ann-Lii Cheng

Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.